Gravity Analytica

Vistagen to Present at the Stifel 2024 Healthcare Conference

VTGN 11.14.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-18

Name of Upcoming Event:Stifel 2024 Healthcare Conference

Full Press Release SEC Filings Our VTGN Tweets

About Gravity Analytica

Recent Filings

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 14, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking placeNovember 18and 19, 2024 inNew York City.

Stifel 2024 Healthcare Conference

Shawn Singh, Chief Executive Officer, will participate in a fireside chat onMonday, November 18at3:35 p.m. Eastern Time.

A webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website atwww.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative.

About Vistagen

Headquartered inSouth San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage company leveraging its pioneering neuroscience and deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of intranasal product candidates called pherines. Each pherine product candidate in Vistagen’s neuroscience pipeline is designed to rapidly activate olfactory system and brain neurocircuitry to achieve desired therapeutic benefits and differentiated safety without requiring systemic absorption or binding to neurons in the brain. Vistagen’s neuroscience pipeline also includes an oral prodrug, AV-101, with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent disorders, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect atwww.Vistagen.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241114792150/en/

Investors:Mark A. McPartlandVistagen Therapeuticsmarkmcp@vistagen.com

Media:Caren ScannellVistagen Therapeuticscscannell@vistagen.com

Source: Vistagen

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com